Insights on hospital structure and utilization, physician treatment selection criteria, and reimbursement are delved into.

Physician’s brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others affecting brand usage have been covered.

Future trends such as investment in breakthrough innovations like GE Healthcare’s new contrast enhanced mammography solution for biopsy called Serena Bright are expected to be potential disruptors in the market.

Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such as FDA approval of MammoScreen an artificial intelligence-based software by Therapixel; partnership between Fujifilm and ScreenPoint Medical Partner to incorporate ScreenPoint Medical Partner’s FDA approved Transpara, an artificial intelligence-based breast cancer detection platform with Fujifilm’s ASPIRE Cristalle mammography system for 2D and 3D mammography are covered in the report.